Skip to main content
575 search results for:

Nateglinide 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-04-2020 | Stroke | OriginalPaper

    Nateglinide Exerts Neuroprotective Effects via Downregulation of HIF-1α/TIM-3 Inflammatory Pathway and Promotion of Caveolin-1 Expression in the Rat’s Hippocampus Subjected to Focal Cerebral Ischemia/Reperfusion Injury

    Ischemic stroke is a major cause of death and motor disabilities all over the world. It is a muti-factorial disorder associated with inflammatory, apoptotic, and oxidative responses. Nateglinide (NAT), an insulinotropic agent used for the …

  2. 01-07-2013 | OriginalPaper

    Improved post-prandial ghrelin response by nateglinide or acarbose therapy contributes to glucose stability in Type 2 diabetic patients

    Background: Recent studies highlight an important role of ghrelin in glucose homeostasis, while the association between ghrelin regulation and glucose fluctuation is unclear. Aim: We compared the effects of two postprandial hypoglycemic agents on …

  3. 01-09-2000 | OriginalPaper

    Nateglinide

    Nateglinide is a novel D-phenylalanine derivative that inhibits ATP-sensitive K+ channels in pancreatic β-cells in the presence of glucose and thereby stimulates the prandial release of insulin.▴ Nateglinide reduces fasting and mealtime blood …

  4. 01-09-2000 | OriginalPaper

    Nateglinide

    A Viewpoint by Willy J. Malaisse
  5. 01-09-2000 | OriginalPaper

    Nateglinide

    A Viewpoint by Riccardo Perfetti
  6. 01-06-2003 | Abstract

    Nateglinide

    First report of hypoglycaemia: case report
  7. 01-04-2005 | Abstract

    Nateglinide overdose

    Hypoglycaemia: case report
  8. 01-12-2007 | Abstract

    Nateglinide overdose

    Hypoglycaemia treated with octreotide in an elderly patient: case report
  9. 01-06-2000 | OriginalPaper

    Nateglinide, a New Mealtime Glucose Regulator

    Lack of Pharmacokinetic Interaction with Digoxin in Healthy Volunteers

    Objective: To investigate any possible pharmacokinetic interactions that may occur following the coadministration of nateglinide, a new mealtime glucose regulator, and digoxin. Design and Setting: This was a partially randomised, three-period …

  10. 01-12-2005 | Abstract

    Hypoglycaemia risk favours nateglinide-based therapy

  11. 01-05-2003 | OriginalPaper

    Nateglinide reduces postprandial glucose levels, with a low risk of hypoglycaemia in patients with type 2 diabetes mellitus

  12. 01-03-2013 | OriginalPaper

    Nateglinide in Combination with Metformin in Chinese Patients with Type 2 Diabetes Mellitus: A Post-Marketing Surveillance Study

    The incidence of diabetes mellitus is increasing globally. Rapid changes in lifestyle in China have brought about a greater prevalence of diabetes in this country [ 1 – 3 ]. In a recent cross-sectional study involving a nationally representative …

  13. 01-03-2012 | OriginalPaper

    Comparison of the rapidity of onset of the therapeutic effect between nateglinide and mitiglinide by PK/PD analysis in rats

    Nateglinide and mitiglinide are immediate short-acting insulinotropic agents. Both are administered preprandially to control postprandial hyperglycemia. Glinide drugs are characterized by immediate onset as well as rapid disappearance of effect as …

  14. 01-07-2018 | OriginalPaper

    Efficacy and safety of nateglinide plus sitagliptin combination therapy in type 2 diabetes patients inadequately controlled by sitagliptin monotherapy: a phase 3, multicenter, open-label, long-term study

    Nateglinide is classified as a rapid-acting insulin secretagog glinide, and as with sulfonylurea (SU), it acts on the SU receptor on the surface of cellular membranes of pancreatic β-cells and improves the postprandial glycemic control of type 2 …

  15. 01-11-2003 | OriginalPaper

    Clinical characteristics of nateglinide response as assessed by insulinogenic indices: Preliminary study to determine an optimal indication for nateglinide

    Insulin secretion dynamics and response to nateglinide were studied in patients with type 2 diabetes and reduced early-phase insulin secretion. On day 1, 24 patients underwent a 75-g oral glucose tolerance test without taking nateglinide. On day …

  16. 01-02-2004 | ReviewPaper

    Clinical Pharmacokinetics of Nateglinide

    A Rapidly-Absorbed, Short-Acting Insulinotropic Agent

    The prevalence and medical and economic impact of type 2 diabetes mellitus is increasing in Western societies. New agents have been developed that act primarily to reduce postprandial glucose excursions, which may be of particular significance now …

  17. 01-09-2005 | OriginalPaper

    Postmarketing surveillance study of nateglinide in Japan

    Nateglinide is an oral antidiabetic medication that acts through rapid, short-term stimulation of insulin production. This study was undertaken to identify the incidence and nature of adverse effects of nateglinide and to assess its efficacy in …

  18. Open Access 01-12-2016 | OriginalPaper

    Effects of nateglinide and rosiglitazone on pancreatic alpha- and beta-cells, GLP-1 secretion and inflammatory markers in patients with type 2 diabetes: randomized crossover clinical study

    Cardiovascular disease is the leading cause of mortality in patients with type 2 diabetes mellitus. The rigorous control of glycemia can delay but not prevent vascular complications, which are probably related to many other poorly controlled …

  19. 01-03-2003 | OriginalPaper

    The mechanisms underlying the unique pharmacodynamics of nateglinide

    AbstractNateglinide, a D-phenylalanine derivative, belongs to a new group of insulinotropic agents with rapid onset and short duration of action. These agents have been developed to reduce the risk of hypoglycaemia associated with pharmacological …

  20. 01-12-2009 | OriginalPaper

    Nateglinide versus repaglinide for type 2 diabetes mellitus in China

    The purpose of this study is to evaluate efficacy and safety of nateglinide tablet administration in comparison with those of repaglinide tablet as control on treating type 2 diabetes mellitus in China. Pooled-analysis with analysis of covariance …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.